New hope for leukemia patients who have run out of options
NCT ID NCT07245251
First seen Nov 25, 2025 · Last updated May 16, 2026 · Updated 20 times
Summary
This early-stage study tests an experimental drug called STR-P004 in 11 adults with relapsed or treatment-resistant CD19-positive acute lymphoblastic leukemia. The main goals are to check safety and find the right dose, while also looking for signs that the drug can fight the cancer. Participants must be between 18 and 65 years old and have few other treatment choices.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBKASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.